OCUL Ocular Therapeutix, Inc.
Healthcare$8.29+0.73%ClosedMarket Cap: $1.82B
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
3.17
P/S
34.63
EV/EBITDA
-4.31
DCF Value
$-0.49
FCF Yield
-13.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.2%
Operating Margin
-575.4%
Net Margin
-558.2%
ROE
-64.6%
ROA
-39.7%
ROIC
-43.5%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $10.8M | 87.7% | $-93.3M | $-88.6M | $— | — |
| Q4 null | $13.3M | 88.0% | $-69.8M | $-64.7M | $— | — |
| FY null | $51.8M | 87.3% | $-270.0M | $-265.9M | $— | — |
| Q3 null | $14.5M | 87.8% | $-68.7M | $-69.4M | $— | — |
| Q2 null | $13.5M | 85.6% | $-67.6M | $-67.8M | $— | — |
| Q1 null | $10.7M | 88.2% | $-63.9M | $-64.1M | $— | — |
| Q4 null | $17.1M | 92.8% | $-50.6M | $-48.4M | $— | — |
| FY null | $63.7M | 91.2% | $-171.8M | $-193.5M | $— | — |
| Q3 null | $15.4M | 89.9% | $-46.0M | $-36.5M | $— | — |
| Q2 null | $16.4M | 90.8% | $-43.6M | $-43.8M | $— | — |
| Q1 null | $14.8M | 91.0% | $-31.6M | $-64.8M | $— | — |
| Q4 2023 | $14.8M | 90.6% | $-20.1M | $-29.2M | $-0.20 | — |